List of Excipients in Branded Drug INSULIN LISPRO PROTAMINE AND INSULIN LISPRO INJECTABLE SUSPENSION

« Back to Dashboard

Insulin Lispro Protamine and Insulin Lispro Injectable Suspension: Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: September 6, 2026

Insulin lispro protamine and insulin lispro injectable suspension is the active pharmaceutical ingredient combination used in Humalog Mix 75/25, a premixed insulin containing 75% insulin lispro protamine suspension and 25% insulin lispro. The commercial opportunity is concentrated in follow-on biologics, formulation improvement, device integration, supply-chain resilience, and regional competition rather than in conventional small-molecule generic substitution.

The formulation depends on a narrow excipient system. Protamine and zinc control the intermediate-acting fraction, while preservatives, phosphate, glycerol, and pH adjustment maintain sterility, suspension stability, dose uniformity, and injection performance. Any competing product must reproduce the clinical and physicochemical behavior of the reference suspension, not merely match the insulin amino-acid sequence.

What is insulin lispro protamine and insulin lispro injectable suspension?

Humalog Mix 75/25 is a subcutaneous premix containing:

Component	Function
Insulin lispro	Rapid-acting insulin fraction
Insulin lispro protamine suspension	Intermediate-acting fraction
Protamine	Forms a less-soluble insulin complex and prolongs absorption
Zinc	Supports insulin association and suspension structure
Dibasic sodium phosphate	Buffering capacity
Glycerol	Tonicity and formulation support
Metacresol and phenol	Antimicrobial preservatives
Hydrochloric acid and sodium hydroxide	pH adjustment
Water for injection	Vehicle

The labeled product contains 100 units/mL, with 25 units of insulin lispro and 75 units of insulin lispro protamine per mL. The product is a cloudy suspension that must be resuspended before injection. The suspension characteristic is central to dose reproducibility and is a major technical barrier for competitors. [1]

What excipients protect the commercial performance of Humalog Mix 75/25?

The excipient system is primarily functional rather than ornamental. Each material contributes to the product’s stability, sterility, delivery profile, or manufacturability.

Protamine and zinc

Protamine is the defining excipient for the intermediate-acting fraction. It interacts with insulin lispro to create a less-soluble complex. Particle size, complexation ratio, mixing order, temperature, and maturation time can affect sedimentation, redispersion, and absorption.

Zinc supports insulin hexamer formation and contributes to the physical state of the suspension. Changes in zinc concentration can alter aggregation, particle morphology, dissolution, and pharmacokinetics.

These materials create a formulation barrier that is more substantial than the preservative system. A follow-on manufacturer must establish equivalent suspension behavior and exposure for both the rapid and intermediate components.

Metacresol and phenol

Metacresol and phenol provide antimicrobial preservation for the multidose injectable product. Preservative concentration affects:

• Sterility assurance after repeated needle puncture
• Local tolerability
• Protein stability
• Adsorption to container surfaces
• Compatibility with pen cartridges and injection devices

A preservative-free version could address sensitivity or tolerability concerns, but it would require a different container-closure and presentation strategy. The opportunity is more credible in single-use or unit-dose formats than in conventional multidose pens.

Phosphate and glycerol

Dibasic sodium phosphate provides buffering and contributes to the formulation’s ionic environment. Glycerol supports tonicity and can influence protein-protein interactions and the physical behavior of suspended particles.

Substituting phosphate with another buffer, such as histidine or citrate, could support a differentiated product, but the change may affect insulin association, protamine complexation, preservative performance, and injection-site tolerability. A buffer substitution would therefore require extensive comparability work.

pH and container closure

The product is formulated within a controlled near-neutral pH range. Small pH changes can affect insulin solubility, protamine binding, zinc coordination, preservative activity, and aggregation.

Container closure is part of the excipient strategy because insulin can adsorb to glass, elastomer, and plastic surfaces. Silicone oil, tungsten residues, extractables, and leachables can also affect protein quality and particle formation. Cartridge material and stopper chemistry are potential sources of non-infringing differentiation and product risk.

What patents protect insulin lispro protamine and insulin lispro injectable suspension?

The historical patent estate was built around insulin lispro, insulin analog formulations, protamine-complexed insulin, delivery systems, and manufacturing processes. The principal composition-of-matter protection for insulin lispro is no longer a current U.S. barrier.

Patent or protection category	Relevance	Commercial status
Insulin lispro composition patents	Protect the lispro analog and related sequences	Core U.S. protection expired
Insulin analog formulation patents	Cover stabilized insulin formulations and excipient systems	Relevant claims may have expired or require claim-by-claim review
Protamine-complex formulation claims	Potentially cover suspension composition, ratios, and preparation	Scope depends on jurisdiction and claim language
Device and cartridge patents	Cover pens, reservoirs, dose mechanisms, and delivery systems	Can remain relevant after drug patents expire
Manufacturing-process patents	Cover mixing, crystallization, particle control, filling, or sterilization	Potentially material for biosimilar manufacturing
Method-of-use patents	May cover treatment regimens or administration schedules	Product-specific scope must be checked in each jurisdiction

U.S. Patent No. 5,514,646, assigned to Eli Lilly, is a foundational insulin lispro patent. Its effective U.S. term ended in the mid-2010s, subject to patent-term calculations and any applicable regulatory extension. It does not provide current broad exclusivity over insulin lispro products. [2]

The commercial distinction is important: expired composition patents do not eliminate risk from manufacturing, formulation, device, trade-secret, or foreign patents. A competitor can avoid a formulation claim while still facing process or device claims.

What is the Orange Book status of Humalog Mix 75/25?

Humalog Mix 75/25 was historically listed in the FDA Orange Book as a drug product. However, insulin products transitioned from the Federal Food, Drug, and Cosmetic Act pathway to the Public Health Service Act biologics framework on March 23, 2020. FDA now treats insulin products as biologics for approval and biosimilar purposes. [3]

The relevant regulatory pathway is therefore generally Section 351(k) of the Public Health Service Act, rather than a conventional abbreviated new drug application under Section 505(j).

Issue	Implication
Reference product	Humalog Mix 75/25
Active components	Insulin lispro and insulin lispro protamine
Current regulatory framework	Biologic under the Public Health Service Act
Likely follow-on pathway	351(k) biosimilar or interchangeable insulin pathway
Conventional ANDA substitution	Generally not the principal pathway for a new follow-on insulin
Orange Book relevance	Historical and transitional patent information remains relevant, but Purple Book and biologics rules are increasingly important

A company developing a follow-on product should not assume that the absence of a current Orange Book patent listing eliminates all U.S. freedom-to-operate risk.

When does insulin lispro Mix 75/25 lose exclusivity?

The key U.S. product-level exclusivity barriers have largely expired. Insulin lispro’s core patent protection expired years ago, and Humalog Mix 75/25 no longer benefits from meaningful new-molecule exclusivity.

The practical market-entry position is:

Exclusivity type	Approximate position
Insulin lispro composition patent	Expired in the United States
New chemical entity exclusivity	Not a current barrier
Pediatric exclusivity	Historical, not a current barrier
Reference biologic exclusivity	Historical transition-era protection; no current practical barrier comparable to a newly approved biologic
Device exclusivity	May remain relevant for specific pen or cartridge designs
Formulation and process patents	Must be reviewed individually
Trade secrets	Potentially material and indefinite if properly maintained

The most important remaining barriers are regulatory comparability, manufacturing capability, clinical development, device access, and payer adoption.

What Paragraph IV challenges and biosimilar risks affect Humalog Mix 75/25?

Paragraph IV litigation is less central after the transition of insulin products into the biologics framework. A conventional ANDA applicant would use Paragraph IV certification against listed patents. A biosimilar applicant instead faces the biologics patent dance under Section 351(l), including patent-information exchanges and potential infringement litigation.

No FDA-approved biosimilar or interchangeable product specifically referencing Humalog Mix 75/25 was publicly identified through June 2024. That absence does not indicate durable exclusivity. It reflects the technical complexity of demonstrating similarity for a premixed suspension containing two pharmacologically distinct insulin fractions.

The largest biosimilar development risks are:

1. Matching the rapid-acting lispro fraction.
2. Matching the protamine-complexed intermediate fraction.
3. Demonstrating equivalent particle-size distribution and redispersion.
4. Establishing comparable pharmacokinetics for both components.
5. Controlling batch-to-batch suspension uniformity.
6. Securing compatible pen, cartridge, or vial presentations.
7. Managing immunogenicity and anti-insulin antibody data.

An applicant may seek approval as a biosimilar without interchangeability. Interchangeability could improve pharmacy-level substitution, but it generally requires a higher evidentiary and switching burden.

How strong is the patent estate for Humalog Mix 75/25?

The patent estate is likely moderate to weak at the composition level and stronger at the process and device levels.

Composition strength

Broad claims covering insulin lispro are no longer commercially decisive in the United States. The basic active ingredient is established, and the reference product has a long clinical history.

Formulation strength

Formulation claims may remain relevant where they cover:

• Specific protamine-to-insulin ratios
• Zinc concentrations
• Particle-size distributions
• Buffer and preservative combinations
• Stability limits
• Redispersion performance
• Manufacturing conditions that produce a defined suspension

The enforceability of these claims depends on expiration dates, claim construction, prosecution history, and whether a competitor’s product meets all limitations.

Process strength

Process patents and undisclosed know-how may create the strongest practical barrier. A competitor can theoretically use different equipment or process parameters, but it must still achieve comparable product quality. The critical know-how may include order of addition, shear profile, temperature control, hold times, bulk handling, filling, and resuspension specifications.

Device strength

Lilly’s pen and cartridge architecture can create a separate barrier. A competitor can avoid this risk with a vial, a licensed third-party pen, or a distinct cartridge and dose-delivery mechanism.

What commercial opportunities exist for excipient innovation?

Lower-preservative or preservative-free products

A preservative-reduced product could target patients with local reactions or repeated-use tolerability concerns. The most commercially practical format would be a single-use pen or cartridge that reduces the need for multidose antimicrobial preservation.

Improved redispersion

A product that resuspends with fewer inversions or less vigorous agitation could reduce dosing errors. This opportunity requires measurable advantages in sedimentation rate, particle-size distribution, dose uniformity, and user handling.

Extended in-use stability

Longer in-use stability at controlled room temperature could reduce waste and improve use in markets with limited refrigeration. The product would need to maintain potency, impurity profile, sterility, preservative effectiveness, and suspension performance throughout the claimed period.

Reduced injection volume

The standard product is U-100. A concentrated premix could reduce injection volume for patients requiring high insulin doses. The technical risks include dosing errors, altered absorption, device calibration, and difficulty maintaining the intended 75:25 ratio.

Alternative buffers and stabilizers

Histidine, citrate, amino acids, surfactants, or polyols could support a redesigned formulation. Surfactants may reduce interfacial aggregation but can introduce new risks involving peroxide impurities, extractables, and injection tolerability.

Digital and device integration

A pen that records dose timing, confirms resuspension behavior, or connects with glucose-monitoring systems could support premium positioning. Device differentiation is less dependent on active-ingredient patent protection and can support licensing or co-development transactions.

How does Humalog Mix 75/25 compare with competing premixed insulins?

Product	Rapid fraction	Intermediate fraction	Strategic distinction
Humalog Mix 75/25	25% insulin lispro	75% insulin lispro protamine	Lilly reference product; lispro-based
NovoLog Mix 70/30	30% insulin aspart	70% insulin aspart protamine	Novo Nordisk competing analog premix
Human premixed insulin 70/30	30% regular human insulin	70% NPH insulin	Lower-cost human insulin alternative
Insulin lispro Mix 50/50	50% insulin lispro	50% insulin lispro protamine	Higher rapid-acting fraction

The closest branded competitor is NovoLog Mix 70/30. The competitive issue is not only patent coverage. Prescriber familiarity, formulary placement, pen availability, patient training, and clinical preference can be more important than molecular differentiation.

Which companies are challenging the market?

The competitive field includes:

• Eli Lilly, as the reference-product sponsor
• Novo Nordisk, with insulin aspart premix products
• Biocon Biologics and Viatris, which have commercial insulin follow-on capabilities
• Wockhardt and regional insulin manufacturers
• Ypsomed and other device companies, where licensed delivery platforms support market entry
• Contract development and manufacturing organizations with recombinant insulin and sterile-fill capabilities

A direct Humalog Mix 75/25 competitor must combine recombinant insulin production with protamine suspension technology, device supply, regulatory capability, and payer access. Many insulin manufacturers can produce insulin, but fewer have demonstrated capability with complex premixed analog suspensions.

What generic launch scenarios exist for insulin lispro Mix 75/25?

Scenario 1: Biosimilar vial

This is the lowest device complexity route but may have weaker commercial differentiation. It can target hospitals, public tenders, and price-sensitive markets.

Scenario 2: Biosimilar prefilled pen

This route has higher development and device costs but improves patient convenience and pharmacy acceptance. It also creates more potential patent exposure through cartridge and pen components.

Scenario 3: Regional formulation license

A manufacturer could license insulin lispro, protamine technology, or a complete drug-device combination. This approach reduces development time but creates royalty and supply dependence.

Scenario 4: Reformulated follow-on product

A differentiated product with improved resuspension, reduced preservatives, longer in-use stability, or a new device could compete without positioning solely on price.

Scenario 5: Hospital and tender product

A vial-based product could compete in government procurement and institutional channels, where device features have limited value and acquisition cost dominates.

What manufacturing and IP barriers matter most?

The principal barriers are:

• Recombinant insulin production at commercial scale
• Correct lispro folding and impurity control
• Protamine complexation reproducibility
• Zinc and buffer control
• Suspension particle engineering
• Aseptic processing and sterile filtration strategy
• Container-closure compatibility
• In-use sterility and preservative effectiveness
• Analytical methods that distinguish free and complexed insulin
• Pharmacokinetic comparability for both insulin fractions
• Device and cartridge qualification
• Global regulatory filing consistency

Manufacturing know-how may be more valuable than expired active-ingredient patents. A product can be legally non-infringing yet commercially unsuccessful if it has inconsistent resuspension or unacceptable device performance.

What is the revenue exposure and market opportunity?

Lilly does not separately disclose revenue for Humalog Mix 75/25 in its public financial reporting. Revenue is generally reported within broader insulin or diabetes-product categories. The commercial exposure is therefore best assessed through total Humalog franchise performance, insulin pricing pressure, market share, and premix utilization.

The strongest opportunities are:

1. Lower-cost biosimilar or follow-on supply in the United States.
2. Public-sector tenders in emerging markets.
3. Improved pen and cartridge presentations.
4. Preservative-reduced or single-use formats.
5. Licensing of protamine-suspension technology.
6. Regional manufacturing partnerships.
7. Supply diversification for insulin-dependent health systems.

Key Takeaways

• Humalog Mix 75/25 contains 25% insulin lispro and 75% insulin lispro protamine.
• Protamine, zinc, phosphate, glycerol, metacresol, phenol, and pH control define the formulation’s performance.
• Core insulin lispro patent protection has expired in the United States.
• Current risk is concentrated in formulation, process, device, manufacturing know-how, and foreign patents.
• The product is regulated under the biologics framework after the 2020 insulin transition.
• A follow-on developer would generally pursue a 351(k) biosimilar strategy rather than a conventional generic pathway.
• The strongest commercial opportunities are improved redispersion, reduced preservatives, new devices, regional licensing, and lower-cost biosimilar supply.
• No FDA-approved biosimilar specifically referencing Humalog Mix 75/25 was publicly identified through June 2024.

FAQs About Insulin Lispro Protamine and Insulin Lispro Injectable Suspension

Is insulin lispro protamine the same as insulin lispro?

No. Insulin lispro is the rapid-acting insulin fraction. Insulin lispro protamine is a less-soluble complex designed to provide a longer intermediate-acting profile.

Can another company make a generic Humalog Mix 75/25?

A company can pursue a follow-on product, but the principal U.S. pathway is generally a biosimilar application under Section 351(k), not a conventional generic application.

Why must Humalog Mix 75/25 be resuspended before injection?

The product is a suspension containing protamine-complexed insulin particles. Resuspension restores a uniform distribution so that the injected dose contains the intended ratio of rapid and intermediate insulin.

Could a preservative-free lispro premix be commercially viable?

Yes, particularly in single-use or unit-dose formats. The product would need an alternative sterility and container-closure strategy because multidose presentations normally rely on antimicrobial preservation.

Does expired insulin lispro patent protection eliminate litigation risk?

No. Competitors can still face claims involving formulation composition, manufacturing processes, delivery devices, cartridges, trademarks, or foreign patent rights.

References

1. U.S. Food and Drug Administration. (2023). Humalog Mix75/25 prescribing information. https://pi.lilly.com/us/humalog-mix7525-pi.pdf
2. U.S. Patent and Trademark Office. (1996). U.S. Patent No. 5,514,646: Insulin lispro. https://patents.google.com/patent/US5514646
3. U.S. Food and Drug Administration. (2020). Transition plans for insulin and other products regulated under the Federal Food, Drug, and Cosmetic Act. https://www.fda.gov/drugs/drug-safety-and-availability/fda-finalizes-guidance-transition-insulin-and-other-products
4. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov
5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
6. U.S. Food and Drug Administration. (2019). Clinical immunogenicity considerations for biosimilar and interchangeable insulin products. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-therapeutic-protein-biosimilars-comparative-analytical-assessment-and-other-quality-considerations